论文部分内容阅读
近年来,痢疾杆菌(简称痢菌),耐药菌株不断出现。可望成为治疗志贺氏菌病有效制剂的新喹酮类药物具有体外抗菌活性强、细菌耐药突变率低和口服吸收好等优点,已被投入临床使用。为进一步评价这类药物的体内抗菌作用,作者对121例重症志贺氏菌病男性住院病人进行了随机分组对照治疗研究,比较丙氟哌酸和氨苄青霉素的临床疗效;粪便和血清中的药物浓度以及相应的最低抑菌浓度(MIC)。丙氟哌酸治疗组60例;氨苄青霉素治疗
In recent years, dysentery bacilli (referred to as dysentery), resistant strains continue to appear. It is expected that new quinolones, which are effective preparations for the treatment of Shigella spp., Have the advantages of strong antibacterial activity in vitro, low mutation rate of bacterial resistance and good oral absorption, and have been put into clinical use. To further evaluate the antibacterial activity of these drugs in vivo, we conducted a randomized controlled study of 121 male hospitalized patients with severe Shigella to compare the efficacy of propofol with ampicillin. The clinical data of fecal and serum drugs Concentration and the corresponding minimum inhibitory concentration (MIC). Prednisolone treatment group 60 cases; ampicillin treatment